Rich66
10-26-2011, 08:37 PM
J Natl Cancer Inst. (http://www.ncbi.nlm.nih.gov/pubmed?term=Bisphosphonate%20use%20after%20estroge n%20receptor%E2%80%93positive%20breast%20cancer%20 and%20risk%20of%20contralateral%20breast%20cancer# ) 2011 Oct 21. [Epub ahead of print]
Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancer.
Monsees GM (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Monsees%20GM%22%5bAuthor%5d), Malone KE (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Malone%20KE%22%5bAuthor%5d), Tang MT (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Tang%20MT%22%5bAuthor%5d), Newcomb PA (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Newcomb%20PA%22%5bAuthor%5d), Li CI (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Li%20CI%22%5bAuthor%5d).
LINK (http://jnci.oxfordjournals.org/content/early/2011/10/18/jnci.djr399.long)
Source
Affiliations of authors: Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (GMM, KEM, M-TCT, PAN, CIL); Department of Epidemiology, University of Washington, Seattle, WA (GMM, KEM, PAN, CIL).
Abstract
Background
A growing body of evidence suggests that nitrogenous bisphosphonates may reduce the risk of developing a first breast cancer and may prevent metastases among breast cancer survivors. However, their impact on risk of second primary contralateral breast cancer is uncertain.
Methods
Within a nested case-control study among women diagnosed with a first primary estrogen receptor-positive invasive breast cancer at ages 40-79 years, we assessed the association between post-diagnostic bisphosphonate use and risk of second primary contralateral breast cancer. We used multivariable-adjusted conditional logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) comparing 351 contralateral breast cancer case subjects with 662 control subjects (ie, breast cancer patients not diagnosed with contralateral breast cancer) who were incidence density-matched on county; race/ethnicity; and age at, year of, and stage at first breast cancer diagnosis. We performed sensitivity analyses with respect to bisphosphonate type and confounding by indication. All statistical tests were two-sided.
Results
Current use of any nitrogenous bisphosphonate and use specifically of alendronate were both associated with reduced risks of contralateral breast cancer compared with never use (OR = 0.41, 95% CI = 0.20 to 0.84 and OR = 0.39, 95% CI = 0.18 to 0.88, respectively). The risk of contralateral breast cancer further declined with longer durations of bisphosphonate use among current users (P(trend) = .03). Results were similar in analyses restricted to patients with a history of osteoporosis or osteopenia.
Conclusions
Bisphosphonate use was associated with a substantial reduction in risk of contralateral breast cancer. If this finding is confirmed in additional studies, nitrogenous bisphosphonate therapy may be a feasible approach for contralateral breast cancer risk reduction.
<dl class="ecxrprtid"><dt>PMID:</dt><dd>22021667</dd><dd> [PubMed - as supplied by publisher] </dd></dl>
Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancer.
Monsees GM (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Monsees%20GM%22%5bAuthor%5d), Malone KE (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Malone%20KE%22%5bAuthor%5d), Tang MT (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Tang%20MT%22%5bAuthor%5d), Newcomb PA (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Newcomb%20PA%22%5bAuthor%5d), Li CI (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Li%20CI%22%5bAuthor%5d).
LINK (http://jnci.oxfordjournals.org/content/early/2011/10/18/jnci.djr399.long)
Source
Affiliations of authors: Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (GMM, KEM, M-TCT, PAN, CIL); Department of Epidemiology, University of Washington, Seattle, WA (GMM, KEM, PAN, CIL).
Abstract
Background
A growing body of evidence suggests that nitrogenous bisphosphonates may reduce the risk of developing a first breast cancer and may prevent metastases among breast cancer survivors. However, their impact on risk of second primary contralateral breast cancer is uncertain.
Methods
Within a nested case-control study among women diagnosed with a first primary estrogen receptor-positive invasive breast cancer at ages 40-79 years, we assessed the association between post-diagnostic bisphosphonate use and risk of second primary contralateral breast cancer. We used multivariable-adjusted conditional logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) comparing 351 contralateral breast cancer case subjects with 662 control subjects (ie, breast cancer patients not diagnosed with contralateral breast cancer) who were incidence density-matched on county; race/ethnicity; and age at, year of, and stage at first breast cancer diagnosis. We performed sensitivity analyses with respect to bisphosphonate type and confounding by indication. All statistical tests were two-sided.
Results
Current use of any nitrogenous bisphosphonate and use specifically of alendronate were both associated with reduced risks of contralateral breast cancer compared with never use (OR = 0.41, 95% CI = 0.20 to 0.84 and OR = 0.39, 95% CI = 0.18 to 0.88, respectively). The risk of contralateral breast cancer further declined with longer durations of bisphosphonate use among current users (P(trend) = .03). Results were similar in analyses restricted to patients with a history of osteoporosis or osteopenia.
Conclusions
Bisphosphonate use was associated with a substantial reduction in risk of contralateral breast cancer. If this finding is confirmed in additional studies, nitrogenous bisphosphonate therapy may be a feasible approach for contralateral breast cancer risk reduction.
<dl class="ecxrprtid"><dt>PMID:</dt><dd>22021667</dd><dd> [PubMed - as supplied by publisher] </dd></dl>